Capsid inhibitors for the treatment of HIV
Summary
The USPTO granted Patent US12594267B2 to Gilead Sciences, Inc. covering capsid inhibitor compounds of Formula (Ia) and (Ib) for treating HIV infections in heavily treatment-experienced patients with multidrug resistant HIV. The patent includes 13 claims and lists inventors Anna Chiu, Charles William Rowe, and Scott P. Sellers.
What changed
USPTO granted a new patent to Gilead Sciences covering HIV capsid inhibitor compounds useful in treating multidrug resistant HIV infections in heavily treatment-experienced patients. The patent covers specific chemical formulations and their pharmaceutical applications.
For Gilead and other pharmaceutical companies developing HIV treatments, this patent establishes proprietary rights over a specific class of capsid inhibitors, potentially limiting generic competition in this treatment area. Competitors developing similar compounds will need to design around these claims or seek licensing arrangements.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Capsid inhibitors for the treatment of HIV
Grant US12594267B2 Kind: B2 Apr 07, 2026
Assignee
Gilead Sciences, Inc.
Inventors
Anna Chiu, Charles William Rowe, Scott P. Sellers
Abstract
The present disclosure relates to compounds of Formula (Ia) and (Ib):
or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
CPC Classifications
A61K 2300/00 A61K 31/34 A61K 31/4418 A61K 31/4427 A61K 31/4439 A61K 31/536 A61K 31/5365 A61K 31/685 A61K 45/06 A61K 47/10 A61K 9/0019 A61K 9/0053 A61K 9/0095 A61K 9/08 A61K 9/2018 A61K 9/4825 A61K 9/4858 A61P 31/18
Filing Date
2024-02-27
Application No.
18588730
Claims
13
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.